Acerus Pharmaceuticals (FRA:3TP0) FCF Margin % : -1,073.65% (As of Sep. 2022)

View and export this data going back to 2014. Start your Free Trial

What is Acerus Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Acerus Pharmaceuticals's Free Cash Flow for the three months ended in Sep. 2022 was €-8.35 Mil. Acerus Pharmaceuticals's Revenue for the three months ended in Sep. 2022 was €0.78 Mil. Therefore, Acerus Pharmaceuticals's FCF Margin % for the quarter that ended in Sep. 2022 was -1,073.65%.

As of today, Acerus Pharmaceuticals's current FCF Yield % is 0.00%.

The historical rank and industry rank for Acerus Pharmaceuticals's FCF Margin % or its related term are showing as below:

FRA:3TP0' s FCF Margin % Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0
Current: -917.09

FRA:3TP0's FCF Margin % is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.06 vs FRA:3TP0: -917.09

Acerus Pharmaceuticals FCF Margin % Historical Data

The historical data trend for Acerus Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acerus Pharmaceuticals FCF Margin % Chart

Acerus Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

FCF Margin %

Get a 7-Day Free Trial

1.52

-86.43

-305.13

-2,042.71

570.72

Acerus Pharmaceuticals Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
FCF Margin %	Get a 7-Day Free Trial															-768.14	-983.31	-685.21	-916.53	-1,073.65

Competitive Comparison of Acerus Pharmaceuticals's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Acerus Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acerus Pharmaceuticals's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acerus Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Acerus Pharmaceuticals's FCF Margin % falls into.

Acerus Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Acerus Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2021 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2021 )	/	Revenue (A: Dec. 2021 )
	=	-20.877	/	-3.658
	=	570.72 %

Acerus Pharmaceuticals's FCF Margin for the quarter that ended in Sep. 2022 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2022 )	/	Revenue (Q: Sep. 2022 )
	=	-8.353	/	0.778
	=	-1,073.65 %

Acerus Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of Acerus Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Acerus Pharmaceuticals (FRA:3TP0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acerus Pharmaceuticals Corp (FRA:3TP0) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

7025 Langer Drive, Suite 205, Mississauga, ON, CAN, L5N 0E8

Website

https://www.aceruspharma.com

Acerus Pharmaceuticals Corp is a specialty pharmaceutical company focused on the development, manufacture, marketing and distribution of branded products that improve patient experience, with a primary focus on the field of men's health. Its foundational product includes NATESTO, a testosterone therapy based on nasal gel technology. The company commercializes its products via its salesforce in the United States and Canada, and through a global network of licensed distributors in other territories.

Acerus Pharmaceuticals (FRA:3TP0) Headlines

No Headlines